Skip to main content
. 2024 Sep 3;12(9):815–826. doi: 10.14218/JCTH.2024.00019

Table 3. Clinical trials of FXR agonists.

Drugs Conclusions Phase References
Cilofexor Improvement of MASH Phase II 152,159
MET409 Improvement of MASH Phase I 156
Obeticholic acid Improvement in patients with type 2 diabetes and MASH Phase II 160
Tropifexor Improvement of MASH Phase II 161
Vonafexor Improvement of liver and kidney function in patients with MASH and liver fibrosis Phase II 162

MASH, metabolic dysfunction-associated steatohepatitis.